A Test for Relapse in Estrogen-receptor positive breast cancer using the expression status of few genes

Description:

Novel accelerated progression relapse test can separate patients with good prognosis from those with bad prognosis using an assay of four identified genes at a fraction of the cost of other methods.

Many breast cancer patienst will remain relapse-free even without chemotherapy, however, accepted clinico-pathological variables are unreliable indicators of prognosis. The novel accelerated progression relapse test separates patient with good prognosis from those with a poor prognosis using a simpe assay of four genes. It offers a test for relapse with power comparable to others on the market at a fraction of the cost.

 
Patent Information:
Category(s):
Medical Diagnostics
For Information, Contact:
Richard Cox
Director, Technology Commercialization
University of Notre Dame
(574) 631-5158
rcox4@nd.edu
Inventors:
Steven Buechler
Keywords:
© 2017. All Rights Reserved. Powered by Inteum